Interim CFO
Susan Drexler joined Aileron in June 2022 as Interim Chief Financial Officer (CFO). Susan is an accomplished executive with over 25 years of experience with development- and commercial-stage life science companies in financial management, M&A and licensing deals, financial planning & analysis, and business analytics.
Ms. Drexler was previously CFO with Harmony Biosciences Holdings, Inc., where she oversaw finance, accounting, and IP operations. She led the company’s S-1 process and oversubscribed IPO and managed the company’s transition from a private to a public entity. Previously, Ms. Drexler served as Acting CFO and Vice President, Business Development with Ocugen, Inc. At Ocugen, she established the Business Development function, building a strategy for partnering the company’s early- and late-stage assets, and generating awareness among 40 potential partners in a nine-month timeframe. Prior to that, she served as Senior Director, Strategy and Business Development at Amerisourcebergen Drug Corporation, and subsequently was promoted to Vice President, Business Development and Market Intelligence. Previously, Ms. Drexler served as Director, Corporate Finance with Shire Pharmaceuticals for eight years, responsible for providing financial advice relating to M&A, licensing deals and internal assets evaluation. Prior to Shire, Ms. Drexler held several roles of increasing responsibility over the course of 10 years with Duff & Phelps, LLC (formerly Standard & Poor’s Corporate Value Consulting). She began her career as an audit associate with Goldenberg Rosenthal Friedlander LLP in Jenkintown, PA.
Ms. Drexler received her B.S. in Accounting from Albright College and her M.B.A. in Finance from the Joseph M. Katz Graduate School of Business at the University of Pittsburgh. She is a certified public accountant and a member of the American Institute of Certified Public Accountants.